Survival of European patients diagnosed with myeloid malignancies

A HAEMACARE study

Marc Maynadié, Roberta De Angelis, Rafael Marcos-Gragera, Otto Visser, Claudia Allemani, Carmen Tereanu, Riccardo Capocaccia, Adriano Giacomin, Jean Michel Lutz, Carmen Martos, Risto Sankila, Tom Børge Johannesen, Arianna Simonetti, Milena Sant

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Population-based information on the survival of patients with myeloid malignancies is rare mainly because some entities were not recognized as malignant until the publication of the third revision of the International Classification of Diseases for Oncology and World Health Organization classification in 2000. In this study we report the survival of patients with myeloid malignancies, classified by updated criteria, in Europe. We analyzed 58,800 cases incident between 1995 to 2002 in 48 population-based cancer registries from 20 European countries, classified into HAEMACARE myeloid malignancy groupings. The period approach was used to estimate 5-year relative survival in 2000-2002. The relative overall survival rate was 37%, but varied significantly between the major groups: being 17% for acute myeloid leukemia, 20% for myelodysplastic/myeloproliferative neoplasms, 31% for myelodysplastic syndromes and 63% for myeloproliferative neoplasms. Survival of patients with individual disease entities ranged from 90% for those with essential thrombocythemia to 4% for those with acute myeloid leukemia with multilineage dysplasia. Regional European variations in survival were conspicuous for myeloproliferative neoplasms, with survival rates being lowest in Eastern Europe. This is the first paper to present large-scale, European survival data for patients with myeloid malignancies using prognosis-based groupings of entities defined by the third revision of the International Classification of Diseases for Oncology/World Health Organization classifications. Poor survival in some parts of Europe, particularly for treatable diseases such as chronic myeloid leukemia, is of concern for hematologists and public health authorities.

Original languageEnglish
Pages (from-to)230-238
Number of pages9
JournalHaematologica
Volume98
Issue number2
DOIs
Publication statusPublished - Feb 1 2013

Fingerprint

Survival
Neoplasms
International Classification of Diseases
Acute Myeloid Leukemia
Survival Rate
Essential Thrombocythemia
Eastern Europe
Myelodysplastic Syndromes
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Population
Registries
Publications
Public Health

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Maynadié, M., De Angelis, R., Marcos-Gragera, R., Visser, O., Allemani, C., Tereanu, C., ... Sant, M. (2013). Survival of European patients diagnosed with myeloid malignancies: A HAEMACARE study. Haematologica, 98(2), 230-238. https://doi.org/10.3324/haematol.2012.064014

Survival of European patients diagnosed with myeloid malignancies : A HAEMACARE study. / Maynadié, Marc; De Angelis, Roberta; Marcos-Gragera, Rafael; Visser, Otto; Allemani, Claudia; Tereanu, Carmen; Capocaccia, Riccardo; Giacomin, Adriano; Lutz, Jean Michel; Martos, Carmen; Sankila, Risto; Johannesen, Tom Børge; Simonetti, Arianna; Sant, Milena.

In: Haematologica, Vol. 98, No. 2, 01.02.2013, p. 230-238.

Research output: Contribution to journalArticle

Maynadié, M, De Angelis, R, Marcos-Gragera, R, Visser, O, Allemani, C, Tereanu, C, Capocaccia, R, Giacomin, A, Lutz, JM, Martos, C, Sankila, R, Johannesen, TB, Simonetti, A & Sant, M 2013, 'Survival of European patients diagnosed with myeloid malignancies: A HAEMACARE study', Haematologica, vol. 98, no. 2, pp. 230-238. https://doi.org/10.3324/haematol.2012.064014
Maynadié M, De Angelis R, Marcos-Gragera R, Visser O, Allemani C, Tereanu C et al. Survival of European patients diagnosed with myeloid malignancies: A HAEMACARE study. Haematologica. 2013 Feb 1;98(2):230-238. https://doi.org/10.3324/haematol.2012.064014
Maynadié, Marc ; De Angelis, Roberta ; Marcos-Gragera, Rafael ; Visser, Otto ; Allemani, Claudia ; Tereanu, Carmen ; Capocaccia, Riccardo ; Giacomin, Adriano ; Lutz, Jean Michel ; Martos, Carmen ; Sankila, Risto ; Johannesen, Tom Børge ; Simonetti, Arianna ; Sant, Milena. / Survival of European patients diagnosed with myeloid malignancies : A HAEMACARE study. In: Haematologica. 2013 ; Vol. 98, No. 2. pp. 230-238.
@article{194c364001bc4f40af59326e29a8726c,
title = "Survival of European patients diagnosed with myeloid malignancies: A HAEMACARE study",
abstract = "Population-based information on the survival of patients with myeloid malignancies is rare mainly because some entities were not recognized as malignant until the publication of the third revision of the International Classification of Diseases for Oncology and World Health Organization classification in 2000. In this study we report the survival of patients with myeloid malignancies, classified by updated criteria, in Europe. We analyzed 58,800 cases incident between 1995 to 2002 in 48 population-based cancer registries from 20 European countries, classified into HAEMACARE myeloid malignancy groupings. The period approach was used to estimate 5-year relative survival in 2000-2002. The relative overall survival rate was 37{\%}, but varied significantly between the major groups: being 17{\%} for acute myeloid leukemia, 20{\%} for myelodysplastic/myeloproliferative neoplasms, 31{\%} for myelodysplastic syndromes and 63{\%} for myeloproliferative neoplasms. Survival of patients with individual disease entities ranged from 90{\%} for those with essential thrombocythemia to 4{\%} for those with acute myeloid leukemia with multilineage dysplasia. Regional European variations in survival were conspicuous for myeloproliferative neoplasms, with survival rates being lowest in Eastern Europe. This is the first paper to present large-scale, European survival data for patients with myeloid malignancies using prognosis-based groupings of entities defined by the third revision of the International Classification of Diseases for Oncology/World Health Organization classifications. Poor survival in some parts of Europe, particularly for treatable diseases such as chronic myeloid leukemia, is of concern for hematologists and public health authorities.",
author = "Marc Maynadi{\'e} and {De Angelis}, Roberta and Rafael Marcos-Gragera and Otto Visser and Claudia Allemani and Carmen Tereanu and Riccardo Capocaccia and Adriano Giacomin and Lutz, {Jean Michel} and Carmen Martos and Risto Sankila and Johannesen, {Tom B{\o}rge} and Arianna Simonetti and Milena Sant",
year = "2013",
month = "2",
day = "1",
doi = "10.3324/haematol.2012.064014",
language = "English",
volume = "98",
pages = "230--238",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "2",

}

TY - JOUR

T1 - Survival of European patients diagnosed with myeloid malignancies

T2 - A HAEMACARE study

AU - Maynadié, Marc

AU - De Angelis, Roberta

AU - Marcos-Gragera, Rafael

AU - Visser, Otto

AU - Allemani, Claudia

AU - Tereanu, Carmen

AU - Capocaccia, Riccardo

AU - Giacomin, Adriano

AU - Lutz, Jean Michel

AU - Martos, Carmen

AU - Sankila, Risto

AU - Johannesen, Tom Børge

AU - Simonetti, Arianna

AU - Sant, Milena

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Population-based information on the survival of patients with myeloid malignancies is rare mainly because some entities were not recognized as malignant until the publication of the third revision of the International Classification of Diseases for Oncology and World Health Organization classification in 2000. In this study we report the survival of patients with myeloid malignancies, classified by updated criteria, in Europe. We analyzed 58,800 cases incident between 1995 to 2002 in 48 population-based cancer registries from 20 European countries, classified into HAEMACARE myeloid malignancy groupings. The period approach was used to estimate 5-year relative survival in 2000-2002. The relative overall survival rate was 37%, but varied significantly between the major groups: being 17% for acute myeloid leukemia, 20% for myelodysplastic/myeloproliferative neoplasms, 31% for myelodysplastic syndromes and 63% for myeloproliferative neoplasms. Survival of patients with individual disease entities ranged from 90% for those with essential thrombocythemia to 4% for those with acute myeloid leukemia with multilineage dysplasia. Regional European variations in survival were conspicuous for myeloproliferative neoplasms, with survival rates being lowest in Eastern Europe. This is the first paper to present large-scale, European survival data for patients with myeloid malignancies using prognosis-based groupings of entities defined by the third revision of the International Classification of Diseases for Oncology/World Health Organization classifications. Poor survival in some parts of Europe, particularly for treatable diseases such as chronic myeloid leukemia, is of concern for hematologists and public health authorities.

AB - Population-based information on the survival of patients with myeloid malignancies is rare mainly because some entities were not recognized as malignant until the publication of the third revision of the International Classification of Diseases for Oncology and World Health Organization classification in 2000. In this study we report the survival of patients with myeloid malignancies, classified by updated criteria, in Europe. We analyzed 58,800 cases incident between 1995 to 2002 in 48 population-based cancer registries from 20 European countries, classified into HAEMACARE myeloid malignancy groupings. The period approach was used to estimate 5-year relative survival in 2000-2002. The relative overall survival rate was 37%, but varied significantly between the major groups: being 17% for acute myeloid leukemia, 20% for myelodysplastic/myeloproliferative neoplasms, 31% for myelodysplastic syndromes and 63% for myeloproliferative neoplasms. Survival of patients with individual disease entities ranged from 90% for those with essential thrombocythemia to 4% for those with acute myeloid leukemia with multilineage dysplasia. Regional European variations in survival were conspicuous for myeloproliferative neoplasms, with survival rates being lowest in Eastern Europe. This is the first paper to present large-scale, European survival data for patients with myeloid malignancies using prognosis-based groupings of entities defined by the third revision of the International Classification of Diseases for Oncology/World Health Organization classifications. Poor survival in some parts of Europe, particularly for treatable diseases such as chronic myeloid leukemia, is of concern for hematologists and public health authorities.

UR - http://www.scopus.com/inward/record.url?scp=84875304372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875304372&partnerID=8YFLogxK

U2 - 10.3324/haematol.2012.064014

DO - 10.3324/haematol.2012.064014

M3 - Article

VL - 98

SP - 230

EP - 238

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 2

ER -